Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

18.53
-8.8600-32.35%
Post-market: 18.48-0.0500-0.27%16:00 EDT
Volume:13.76M
Turnover:252.90M
Market Cap:1.89B
PE:-5.57
High:19.10
Open:17.00
Low:16.97
Close:27.39
52wk High:34.29
52wk Low:9.90
Shares:102.21M
Float Shares:102.00M
Volume Ratio:10.20
T/O Rate:13.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3245
EPS(LYR):-3.3245
ROE:-49.16%
ROA:-27.67%
PB:3.21
PE(LYR):-5.57

Loading ...

Top Midday Decliners

MT Newswires Live
·
1 hour ago

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Yesterday

Top Midday Stories: Trump Touts Talks With New Iranian Regime, Renews Threats; Sysco to Acquire Jetro for $29.1 Billion

MT Newswires Live
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY)

TIPRANKS
·
Yesterday

Viridian Therapeutics falls -33.5%

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Yesterday

Viridian Therapeutics down 37% after announcing results from elegrobart trial

TIPRANKS
·
Yesterday

Viridian Therapeutics Exec Says Company Is Sufficiently Funded to Support Operations Through Profitability – Conf Call

THOMSON REUTERS
·
Yesterday

Viridian Therapeutics Exec Says Co Has a Lot of Pricing 'Optionality' for Elegrobart After Late-Stage Data – Conf Call

THOMSON REUTERS
·
Yesterday

Top Premarket Decliners

MT Newswires Live
·
Yesterday

Viridian Therapeutics Shares Down 33.5% Premarket After Co Reports Late‑Stage Trial Data for Its Thyroid Eye Disease Drug

THOMSON REUTERS
·
Yesterday

Viridian's thyroid eye disease drug succeeds in late‑stage trial

Reuters
·
Yesterday

Viridian announces results from elegrobart REVEAL-1 phase 3 trial

TIPRANKS
·
Yesterday

Viridian says elegrobart hits primary endpoint in Phase 3 REVEAL-1 thyroid eye disease trial

Reuters
·
Yesterday

Viridian Therapeutics Inc - Elegrobart Generally Well Tolerated With Low Rates of Hearing Impairment

THOMSON REUTERS
·
Yesterday

Viridian Therapeutics Inc - Reveal-1 Trial Meets Primary Endpoint With Statistically Significant Q4w Proptosis Responder Rate

THOMSON REUTERS
·
Yesterday

Viridian Therapeutics Announces Positive Topline Results From Elegrobart Phase 3 Reveal‑1 Clinical Trial in Active Thyroid Eye Disease

THOMSON REUTERS
·
Yesterday

Wells Fargo Sticks to Their Hold Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Mar 02

Truist Financial Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Feb 27

Analysts’ Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)

TIPRANKS
·
Feb 27